Arcus reports positive Phase 2 interim results for domvanalimab combo in NSCLC

Arcus Biosciences, Inc.

Fourth interim analysis of ARC-7 trial (n=133) shows domvanalimab-containing arms differentiate from zimberelimab monotherapy.
Clinically meaningful improvements in objective response rate, PFS, and six-month landmark PFS observed.
No unexpected safety signals; domvanalimab arms generally well tolerated with safety consistent with individual molecules.
Detailed results to be presented at ASCO Monthly Plenary Series on December 20, 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.